Weimin Li

Weimin (Warren) Li has extensive experience in the pharmaceutical industry, with a focus on translational medicine and pre-clinical research. Weimin (Warren) is currently serving as the VP and Head of Translational Medicine and Pre-Clinical Research at Overland Pharmaceuticals. Prior to this, they held the position of Translational Development Head, Cell Therapies at Takeda from October 2020 to August 2021. Before that, they worked at AstraZeneca as the Director of Oncology Translational Medicine/Precision Medicine from February 2019 to October 2020. Weimin (Warren) also gained experience at MedImmune as the Director of Immuno oncology translational medicine from May 2018 to February 2019. Earlier in their career, they worked at the Janssen Pharmaceutical Companies of Johnson & Johnson, holding roles as Associate Scientific Director, Principal Scientist, and Senior Scientist from 2008 to 2018. Weimin (Warren) started their career at GSK as an Investigator, Principal Scientist, and Bioinformatics Scientist from 2003 to 2008. Weimin (Warren) Li began their professional journey as a Research Associate at The University of Chicago from October 2002 to October 2003.

Weimin (Warren) Li has a Bachelor of Science (B.S.) degree in Biology/Biological Sciences, General from Fudan University. Weimin (Warren) also holds a Doctor of Philosophy (Ph.D.) degree in Biology/Biological Sciences, General from the University of Illinois Urbana-Champaign.